VERU INC (VERU) Stock Price, Quote, News and Overview
NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD
VERU Quote, Performance and Key Statistics
0.5727
-0.02 (-2.88%)
The current stock price of VERU is 0.5727 USD. In the past month the price decreased by -55.26%. In the past year, price decreased by -2.93%.
VERU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| UL | UNILEVER PLC-SPONSORED ADR | 23.29 | 138.82B | ||
| HLN | HALEON PLC-ADR | 23.44 | 45.58B | ||
| KVUE | KENVUE INC | 20.46 | 44.71B | ||
| EL | ESTEE LAUDER COMPANIES-CL A | 30.3 | 25.83B | ||
| BRBR | BELLRING BRANDS INC | 35.08 | 9.36B | ||
| COTY | COTY INC-CL A | 20.39 | 4.98B | ||
| IPAR | INTERPARFUMS INC | 28.81 | 4.30B | ||
| ELF | ELF BEAUTY INC | 23.86 | 4.23B | ||
| ODD | ODDITY TECH LTD-CL A | 22.92 | 2.51B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 10.64 | 1.50B | ||
| OLPX | OLAPLEX HOLDINGS INC | 10.92 | 941.35M | ||
| HLF | HERBALIFE LTD | 4.24 | 837.56M |
Related stock screener links
About VERU
Company Profile
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company is headquartered in Miami, Florida and currently employs 189 full-time employees. The firm is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The firm offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Company Info
VERU INC
2916 N. Miami Avenue, Suite 1000
Miami FLORIDA 33127 US
CEO: Mitchell S. Steiner
Employees: 189
Company Website: https://verupharma.com/
Investor Relations: https://ir.verupharma.com/
Phone: 13125959123
VERU INC / VERU FAQ
What is the stock price of VERU INC today?
The current stock price of VERU is 0.5727 USD. The price decreased by -2.88% in the last trading session.
What is the ticker symbol for VERU INC stock?
The exchange symbol of VERU INC is VERU and it is listed on the Nasdaq exchange.
On which exchange is VERU stock listed?
VERU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERU INC stock?
11 analysts have analysed VERU and the average price target is 3.26 USD. This implies a price increase of 469.93% is expected in the next year compared to the current price of 0.5727. Check the VERU INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERU INC worth?
VERU INC (VERU) has a market capitalization of 83.83M USD. This makes VERU a Micro Cap stock.
How many employees does VERU INC have?
VERU INC (VERU) currently has 189 employees.
What are the support and resistance levels for VERU INC (VERU) stock?
VERU INC (VERU) has a support level at 0.53 and a resistance level at 0.6. Check the full technical report for a detailed analysis of VERU support and resistance levels.
Is VERU INC (VERU) expected to grow?
The Revenue of VERU INC (VERU) is expected to decline by -75.48% in the next year. Check the estimates tab for more information on the VERU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERU INC (VERU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VERU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VERU, evaluating the profitability, health, valuation and growth aspects
- VERU INC (VERU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERU INC (VERU) Sales and EPS estimates to see what analysts future expectations are.
- VERU INC (VERU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERU INC (VERU) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERU INC (VERU) Stock Chart to make your own analysis
- VERU INC (VERU) Latest news and press-releases to stay up to date.
Does VERU INC (VERU) stock pay dividends?
VERU does not pay a dividend.
When does VERU INC (VERU) report earnings?
VERU INC (VERU) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of VERU INC (VERU)?
VERU INC (VERU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the Short Interest ratio of VERU INC (VERU) stock?
The outstanding short interest for VERU INC (VERU) is 12.34% of its float. Check the ownership tab for more information on the VERU short interest.
VERU Technical Analysis
VERU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERU. VERU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VERU Financial Highlights
Over the last trailing twelve months VERU reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 67.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.57% | ||
| ROE | -116.97% | ||
| Debt/Equity | 0.27 |
VERU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to VERU. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 17.67% and a revenue growth -75.48% for VERU